DrugPatentWatch Database Preview
NYMALIZE Drug Profile
or, see our see our flat-rate plans
Which patents cover Nymalize, and what generic alternatives are available?
The generic ingredient in NYMALIZE is nimodipine. There are seven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the nimodipine profile page.
Summary for NYMALIZE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 77 |
| Patent Applications: | 4,444 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | NYMALIZE at DailyMed |
Pharmacology for NYMALIZE
| Ingredient-type | Dihydropyridines |
| Drug Class | Dihydropyridine Calcium Channel Blocker |
| Mechanism of Action | Calcium Channel Antagonists |
Medical Subject Heading (MeSH) Categories for NYMALIZE
Synonyms for NYMALIZE
| 085N594 |
| 1-methylethyl 2-(methyloxy)ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
| 1,?4-?DIHYDRO-?2,?6-?DIMETHYL-?4-?(3-?NITROPHENYL)-?3-?(2-?METHOXYETHYL) 5-?(1-?METHYLETHYL) ESTER,? 3,?5-?PYRIDINEDICARBOXYLIC ACID |
| 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)- |
| 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine-dicarboxylic acid isopropyl 2-methoxyethyl ester |
| 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinecarboxylic acid 2-methoxyethyl 1-methylethyl ester |
| 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid |
| 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester |
| 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester; Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate |
| 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methyloxyethyl 1-methylethyl ester |
| 1,4-Dihydro-2,6-dimethyl-4-(3&prime |
| 1,4-Dihydro-2,6-dimethyl-4-(3′-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl-1-methylethyl Ester |
| 2-Methoxyethyl 1-Methylethyl 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate |
| 2-methoxyethyl propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
| 2-Methoxyethyl-1-methylethyl ester |
| 2,6-dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-beta-methoxyethyl ester 5-isopropyl ester |
| 3-(2-methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
| 3-Isopropyl 5-(2-methoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate # |
| 3-isopropyl 5-(2-methoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
| 3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
| 3,5-pyridinecarboxylic acid 2-methoxyethyl 1-methylethyl ester |
| 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester |
| 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-methoxyethyl 1-methylethyl ester |
| 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl), 2-methoxyethyl 1-methylethyl ester |
| 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-N,N-dimethyl-2,2-diphenyl-butanamide |
| 66085-59-4 |
| AB00053314_05 |
| AB00053314_06 |
| AB00053314-03 |
| AB00053314-04 |
| AB0012346 |
| AB00513963 |
| AB1009471 |
| AC-8484 |
| AC1L1IAS |
| AC1Q4G7S |
| ACT02628 |
| Admon |
| AK163644 |
| AKOS005174934 |
| AKOS015852459 |
| ALBB-015317 |
| Almirall Brand of Nimodipine |
| Alpharma Brand of Nimodipine |
| AN-7970 |
| Andromaco Brand of Nimodipine |
| BAY e 9736 |
| Bay-E 9736 |
| Bay-e-9736 |
| Bayer Brand of Nimodipine |
| Bayvit Brand of Nimodipine |
| BBL028286 |
| BDBM50101971 |
| Bio-0178 |
| Bio1_000118 |
| Bio1_000607 |
| Bio1_001096 |
| Bio2_000117 |
| Bio2_000597 |
| BPBio1_000876 |
| Brainal |
| BRD-8407 |
| BRD-A58048407-001-06-3 |
| BRD8407 |
| BRN 0459792 |
| BSPBio_000796 |
| BSPBio_001397 |
| BSPBio_002412 |
| C07267 |
| C21H26N2O7 |
| Calnit |
| Cantabria Brand of Nimodipine |
| CAS-66085-59-4 |
| CBiol_001832 |
| CCG-101085 |
| CCG-39340 |
| CHEBI:7575 |
| CHEMBL3197349 |
| CPD002530605 |
| CS-2253 |
| CTK8J9033 |
| D00438 |
| D0XN1F |
| DB00393 |
| DivK1c_006812 |
| DR002557 |
| DRG-0139 |
| DSSTox_CID_3370 |
| DSSTox_GSID_23370 |
| DSSTox_RID_76998 |
| DTXSID5023370 |
| EG-1961 |
| EINECS 266-127-0 |
| Elan Brand of Nimodipine |
| Esteve Brand of Nimodipine |
| EU-0100891 |
| FT-0082761 |
| FT-0602600 |
| GTPL2523 |
| HE229490 |
| Hexal Brand of Nimodipine |
| HMS1361F19 |
| HMS1570H18 |
| HMS1791F19 |
| HMS1922E04 |
| HMS1989F19 |
| HMS2052M05 |
| HMS2089H13 |
| HMS2093G11 |
| HMS2097H18 |
| HMS2234B05 |
| HMS3262D04 |
| HMS3266O22 |
| HMS3369G07 |
| HMS3394M05 |
| HMS3402F19 |
| HMS3657I03 |
| HY-B0265 |
| I06-0230 |
| IDI1_033867 |
| isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate |
| isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate |
| Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate |
| isopropyl 2-methoxyethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
| KBio1_001756 |
| KBio2_000117 |
| KBio2_002403 |
| KBio2_002685 |
| KBio2_004971 |
| KBio2_005253 |
| KBio2_007539 |
| KBio3_000233 |
| KBio3_000234 |
| KBio3_001632 |
| KBioGR_000117 |
| KBioGR_001262 |
| KBioSS_000117 |
| KBioSS_002408 |
| Kenesil |
| KS-1304 |
| Lopac0_000891 |
| LP00891 |
| LS-131292 |
| MCULE-4717687158 |
| methylethyl 5-[(2-methoxyethyl)oxycarbonyl]-2,6-dimethyl-4-(3-nitrophenyl)-1,4 -dihydropyridine-3-carboxylate |
| MFCD00153848 |
| MLS000069381 |
| MLS000863294 |
| MLS001076550 |
| MLS001424155 |
| MLS002154061 |
| MLS002172461 |
| MLS003899190 |
| Modus |
| MolPort-001-840-190 |
| N-149 |
| N0896 |
| NC00335 |
| NCGC00015714-04 |
| NCGC00015714-05 |
| NCGC00015714-06 |
| NCGC00015714-07 |
| NCGC00015714-08 |
| NCGC00015714-09 |
| NCGC00015714-10 |
| NCGC00015714-11 |
| NCGC00015714-12 |
| NCGC00015714-13 |
| NCGC00015714-16 |
| NCGC00021456-02 |
| NCGC00024675-02 |
| NCGC00024675-03 |
| NCGC00024675-04 |
| NCGC00024675-05 |
| NCGC00024675-06 |
| NCGC00024675-07 |
| NCGC00024675-08 |
| NCGC00024675-09 |
| NCGC00261576-01 |
| nemotan |
| Nimodipin Hexal |
| Nimodipin ISIS |
| Nimodipin-ISIS |
| nimodipine |
| Nimodipine (Nimotop) |
| Nimodipine (USAN/INN) |
| Nimodipine [USAN:BAN:INN] |
| Nimodipine [USAN:USP:INN:BAN] |
| Nimodipine for peak identification, EuropePharmacopoeia (EP) Reference Standard |
| Nimodipine, British Pharmacopoeia (BP) Reference Standard |
| Nimodipine, European Pharmacopoeia (EP) Reference Standard |
| Nimodipine, pharmaceutical secondary standard; traceable to USP, PhEur and BP |
| Nimodipine, United States Pharmacopeia (USP) Reference Standard |
| NimodipinISIS |
| Nimodipino |
| Nimodipino [INN-Spanish] |
| Nimodipino Bayvit |
| Nimodipinum |
| Nimodipinum [INN-Latin] |
| NimoGel |
| Nimotop |
| NIMOTOP (TN) |
| Nimotop, Nimodipine |
| Nimotop(TM) |
| Nimotop|||Admon|||BAY-e 9736 |
| NimoVent |
| NSC-758476 |
| NSC758476 |
| Nymalize (TN) |
| O5-(2-methoxyethyl) O3-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
| O5-isopropyl O3-(2-methoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
| Opera_ID_14 |
| Periplum |
| Periplum, Nimotop, BRN 0459792, DRG-0139 |
| Pharmakon1600-01503600 |
| Prestwick0_000918 |
| Prestwick1_000918 |
| Prestwick2_000918 |
| Prestwick3_000918 |
| PubChem16211 |
| R2304 |
| Remontal |
| s1747 |
| SAM001246890 |
| SBI-0050866.P003 |
| SC-17122 |
| SCHEMBL34041 |
| SMR000058300 |
| SMR002530605 |
| SPBio_001464 |
| SPBio_002985 |
| SpecPlus_000716 |
| Spectrum_001880 |
| SPECTRUM1503600 |
| Spectrum2_001562 |
| Spectrum3_000766 |
| Spectrum4_000791 |
| Spectrum5_001687 |
| SR-01000075335 |
| SR-01000075335-2 |
| ST082783 |
| STK642934 |
| Tox21_110202 |
| Tox21_110202_1 |
| Tox21_500891 |
| UIAGMCDKSXEBJQ-UHFFFAOYSA-N |
| Vita Brand of Nimodipine |
US Patents and Regulatory Information for NYMALIZE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arbor Pharms Llc | NYMALIZE | nimodipine | SOLUTION;ORAL | 203340-001 | May 10, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
or, see our see our flat-rate plans
or, see our see our flat-rate plans
